News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

OncoPep Initiates Phase 1/2a Clinical Trial with Multi-Peptide Vaccine to Treat Smoldering Multiple Myeloma


1/29/2013 9:49:21 AM

BOSTON--(BUSINESS WIRE)--OncoPep, Inc. today announced that the Company has initiated a Phase 1/2a clinical trial evaluating PVX-410, a multi-peptide therapeutic cancer vaccine, in patients with smoldering multiple myeloma, an asymptomatic precursor of multiple myeloma, which is an incurable cancer of the plasma cells. PVX-410 is composed of four proprietary, synthetic peptides that target specific antigens found on the surface of multiple myeloma cells. Target enrollment for this study is 13 patients. The trial will assess the safety and tolerability of the cancer vaccine, and early-stage data from the study are expected in late 2013.

Read at BioSpace.com

Related News

comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES